source
- Lilly pens another deal, inking up to $5.9B oncology pact with StippleA licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.BioSpace · 8h ago↗ source
- Recon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple BioWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 22h ago↗ source
- IQVIA report finds 90% of drugs launched 2016-2020 unlikely to recoup costsIQVIA analyzed 825 novel medicines launched in the United States between 1991 and 2020 and found that profitability has sharply declined over time. For drugs launched from 2016 to 2020, a positive…